Arthur Andrew Medical was originally established in 1999 under the name Arizona Pharma Group.

Founded by current CEO Justin Andrew Marsh. Mr. Marsh, a former microchip engineer and automation control contractor for companies such as Motorola, Intel and Medtronic, developed the company as a majority investor. The company originally specialized in the importation of enzymes and other raw materials. As a majority of today’s current pharmaceuticals are designed to mimic enzymes, the company strives to develop and discover new medicines through enzyme research and development.

In 2003 Justin Andrew Marsh bought out his minority investors and Arthur Andrew Medical was formed. With the collaboration of well-known enzymologists and best-in-class materials, Arthur Andrew Medical began to create finished products under its own brand-name. In 2003, Neprinol, the world’s most potent systemic enzyme was born. Arthur Andrew’s mission is to be the leader in the development of systemic enzyme products in the enzyme-pharma and supplement industry. While other companies develop products based on market trends and fads, Arthur Andrew Medical only adopts products with ingredients that have extensive clinical research for safety and efficacy.

Arthur Andrew closely monitors the trends of pharmaceutical and ethical drug companies abroad that understand the importance of natural medicine. Many of the enzymes used in our formulas are prescription medications in other countries such as Japan, Germany, and Russia. While the Japanese have focused their efforts in cultivating natural enzymes, drug companies in the US have tried to mimic these natural enzymes in an attempt to patent them for profit. As synthetic enzymes and drugs typically create undesirable side-effects, Arthur Andrew Medical derives and extracts enzymes that can only be found in non-toxic and ethically safe materials such plants, microbes, and other non GMO sources.

The billions in research efforts in designer “natural” enzymes in Japan, has led to the distribution of these wonder drugs here in the US as dietary and prescription medications due to their safety and efficacy. Designer enzymes are manufactured in Japan, by such companies as Honda Engineering and Amano. While most of the true medical applications and research conducted on these enzymes are suppressed by the FDA and FTC, much of this information can be found on websites with countries that have a higher acceptance for non-synthetic or patented medications.

Arthur Andrew Medical understands the importance of legal FDA compliant and truthful marketing and is currently conducting several IRB approved clinical studies. Neprinol our flagship systemic enzyme is currently in phase1 clinical trials at Medicus Research in conjunction with UCLA Medical Center. The study was developed to evaluate the effect of the enzymes ability to support healthy and substantially pristine circulatory health, in otherwise healthy patients that demonstrate high risk markers for heart and circularity dysfunction.

To this end, we understand that much of the evidence and research done overseas does not legally constitute as fact unless these statements have been evaluated by the Food and Drug Administration. Studies like these lay the foundation for future studies that may uncover further evidence for the use of combination therapies including ethical, natural and traditional medicines, for greater efficacy and dramatically lower risk of side effects and preventable deaths.